CD117 expression in breast phyllodes tumors correlates with adverse pathologic parameters and reduced survival

[1]  P. Tan,et al.  Novel genetic aberrations in breast phyllodes tumours: comparison between prognostically distinct groups , 2014, Breast Cancer Research and Treatment.

[2]  P. Tan,et al.  Immunohistochemical expression of homeoproteins Six1 and Pax3 in breast phyllodes tumours correlates with histological grade and clinical outcome , 2014, Histopathology.

[3]  Jinfeng Li,et al.  [WHO classification of tumors of the breast]. , 2014, Zhonghua wai ke za zhi [Chinese journal of surgery].

[4]  Eytan Domany,et al.  c-Kit is suppressed in human colon cancer tissue and contributes to L1-mediated metastasis. , 2013, Cancer research.

[5]  A. D. Van den Abbeele,et al.  Imatinib for melanomas harboring mutationally activated or amplified KIT arising on mucosal, acral, and chronically sun-damaged skin. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  P. Tan,et al.  Phyllodes tumours of the breast: the role of CD34, vascular endothelial growth factor and β‐catenin in histological grading and clinical outcome , 2013, Histopathology.

[7]  Johan Lennartsson,et al.  Stem cell factor receptor/c-Kit: from basic science to clinical implications. , 2012, Physiological reviews.

[8]  P. Tan,et al.  Predicting clinical behaviour of breast phyllodes tumours: a nomogram based on histological criteria and surgical margins , 2011, Journal of Clinical Pathology.

[9]  Jun Wang,et al.  CD34, CD117, and Ki-67 Expression in Phyllodes Tumor of the Breast: An Immunohistochemical Study of 33 Cases , 2011, International Journal of Surgical Pathology.

[10]  M. Colombo,et al.  Tumor-intrinsic and -extrinsic roles of c-Kit: mast cells as the primary off-target of tyrosine kinase inhibitors , 2011, Oncogene.

[11]  A. Kondi-Pafiti,et al.  Expression of c-kit in Common Benign and Malignant Breast Lesions , 2010, Tumori.

[12]  A. Tfayli,et al.  c-Kit expression and mutations in phyllodes tumors of the breast. , 2010, Anticancer research.

[13]  J. S. Lee,et al.  Mutation-Free Expression of c-Kit and PDGFRA in Phyllodes Tumors of the Breast , 2010 .

[14]  W. Hanna,et al.  Expression of c-kit in fibroepithelial lesions of the breast is a mast cell phenomenon , 2008, Modern Pathology.

[15]  P. Loehrer.  Prevalence of KIT Expression in Human Tumors , 2007 .

[16]  K. Yonemori,et al.  Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. , 2006, Pathology, research and practice.

[17]  D. Dabbs,et al.  Phyllodes tumor: a clinicopathologic and immunohistochemical study of 30 cases. , 2006, Archives of pathology & laboratory medicine.

[18]  S. Lade,et al.  KIT immunohistochemistry and mutation status in gastrointestinal stromal tumours (GISTs) evaluated for treatment with imatinib , 2006, Histopathology.

[19]  P. Tan,et al.  p53 and c-kit (CD117) protein expression as prognostic indicators in breast phyllodes tumors: a tissue microarray study , 2005, Modern Pathology.

[20]  F. Milanezi,et al.  c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations? , 2004, Journal of Clinical Pathology.

[21]  R. Scolyer,et al.  Increased c-kit (CD117) expression in malignant mammary phyllodes tumors , 2004, Modern Pathology.

[22]  I. Ellis,et al.  Malignant phyllodes tumours show stromal overexpression of c‐myc and c‐kit , 2003, The Journal of pathology.

[23]  D. Weaver,et al.  c-Kit expression in desmoid fibromatosis. Comparative immunohistochemical evaluation of two commercial antibodies. , 2003, American journal of clinical pathology.

[24]  M. Heinrich,et al.  KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size. , 2002, The American journal of pathology.

[25]  H. Harn,et al.  CD34, CD117, and actin expression in phyllodes tumor of the breast. , 2000, The Journal of surgical research.

[26]  A. D. Tos,et al.  Fibroepithelial tumor [1] , 1995 .